AIRLINK 78.39 Increased By ▲ 5.39 (7.38%)
BOP 5.34 Decreased By ▼ -0.01 (-0.19%)
CNERGY 4.33 Increased By ▲ 0.02 (0.46%)
DFML 30.87 Increased By ▲ 2.32 (8.13%)
DGKC 78.51 Increased By ▲ 4.22 (5.68%)
FCCL 20.58 Increased By ▲ 0.23 (1.13%)
FFBL 32.30 Increased By ▲ 1.40 (4.53%)
FFL 10.22 Increased By ▲ 0.16 (1.59%)
GGL 10.29 Decreased By ▼ -0.10 (-0.96%)
HBL 118.50 Increased By ▲ 2.53 (2.18%)
HUBC 135.10 Increased By ▲ 2.90 (2.19%)
HUMNL 6.87 Increased By ▲ 0.19 (2.84%)
KEL 4.17 Increased By ▲ 0.14 (3.47%)
KOSM 4.73 Increased By ▲ 0.13 (2.83%)
MLCF 38.67 Increased By ▲ 0.13 (0.34%)
OGDC 134.85 Increased By ▲ 1.00 (0.75%)
PAEL 23.40 Decreased By ▼ -0.43 (-1.8%)
PIAA 26.64 Decreased By ▼ -0.49 (-1.81%)
PIBTL 7.02 Increased By ▲ 0.26 (3.85%)
PPL 113.45 Increased By ▲ 0.65 (0.58%)
PRL 27.73 Decreased By ▼ -0.43 (-1.53%)
PTC 14.60 Decreased By ▼ -0.29 (-1.95%)
SEARL 56.50 Increased By ▲ 0.08 (0.14%)
SNGP 66.30 Increased By ▲ 0.50 (0.76%)
SSGC 10.94 Decreased By ▼ -0.07 (-0.64%)
TELE 9.15 Increased By ▲ 0.13 (1.44%)
TPLP 11.67 Decreased By ▼ -0.23 (-1.93%)
TRG 71.43 Increased By ▲ 2.33 (3.37%)
UNITY 24.51 Increased By ▲ 0.80 (3.37%)
WTL 1.33 No Change ▼ 0.00 (0%)
BR100 7,493 Increased By 58.6 (0.79%)
BR30 24,558 Increased By 338.4 (1.4%)
KSE100 72,052 Increased By 692.5 (0.97%)
KSE30 23,808 Increased By 241 (1.02%)

imageKARACHI: A single member bench of Sindh High Court, comprising Justice Mohammad Shafi Siddiqui, through an order on Thursday overthrew the decision by the provincial health authorities to purchase costly hepatitis drug from two multinational companies (MNCs).

The bench acknowledging that this was depriving local pharma companies of level playing ground scraped tender to buy costly hepatitis medicine from MNCs.

Justice Mohammad Shafi Siddiqui who had reserved the judgement on March 6, announcing the same Thursday, termed the process of purchase of medicine illegal, unlawful and without legal grounds; scrapping the tender issued for purchase of medicine worth Rs 250 million.

The detailed judgement came on a petition filed by various local pharmaceutical firms against the rejection of their products used for the treatment of Hepatitis B and C.

Earlier, the court had rejected the plea by the health department for partial purchase of hepatitis medicine from multinationals on the grounds that the court was hearing the case on priority basis therefore limited purchase could not be allowed.

The health authorities had pleaded to relax the stay order on the purchase of injection so that 25 per cent of medicine costing around Rs. 60.2 million could be bought for 33,000 patients, of whom some 1,800 were at terminal stage.

Advocates Faisal Siddiqui, Shahid Memon and Abdus Sattar Pirzada, the counsel for the petitioners, told the court that the government was playing games with mala fide intentions to benefit certain influential, causing great losses to public exchequer and interest of poor hepatitis patients.

They questioned as to why many leading health institutions including Government of Balochistan and Government of AJK had been purchasing and using the locally produced medicines for decades with no complaints, if they were harmful to human health.

The counsel further argued that the government had issued licenses to the local national pharmaceutical firms to produce the drug, allowing it to sell the medicine in local market as well as to export it.

They said one of the drug rejected on quality grounds was the largest selling pharma item in the country and it was produced by Getz Pharma that was the only one in Pakistan having WHO recognition for its laboratory.

The counsel said that the government officials continued to misguide government, masses and the court for their ulterior motives to buy costly medicine from two major multinationals.

Copyright APP (Associated Press of Pakistan), 2015

Comments

Comments are closed.